Immunic (IMUX) to Release Earnings on Wednesday

Immunic (NASDAQ:IMUX) will release its earnings data before the market opens on Wednesday, May 8th. Analysts expect Immunic to post earnings of ($0.27) per share for the quarter.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.03. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $1.30 on Thursday. The stock has a market cap of $117.10 million, a P/E ratio of -0.62 and a beta of 1.93. The firm has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.26. Immunic has a 52-week low of $0.95 and a 52-week high of $3.11.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a report on Saturday, April 27th. Brookline Capital Management restated a “buy” rating and set a $10.00 target price on shares of Immunic in a report on Friday, April 5th.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.